Skip to main content




) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.6%. By the end of trading, Amgen rose $1.58 (2.1%) to $77.96 on average volume. Throughout the day, 4.8 million shares of Amgen exchanged hands as compared to its average daily volume of 4.6 million shares. The stock ranged in a price between $76.60-$78.73 after having opened the day at $77.79 as compared to the previous trading day's close of $76.38. Other companies within the Drugs industry that increased today were:




), up 22.7%,

CytRx Corporation



), up 17.9%,




), up 17.3%, and

Galectin Therapeutics



), up 13.7%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. Amgen has a market cap of $60.3 billion and is part of the

health care

sector. The company has a P/E ratio of 17.9, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 20.7% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Amgen a buy, one analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, attractive valuation levels and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front,

K-V Pharmaceutical Company



), down 14.1%,

Questcor Pharmaceuticals



), down 13.7%,

Sarepta Therapeutics



), down 9.4%, and

Rosetta Genomics



), down 8.4%, were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech